期刊文献+

晚孕期胎盘因子对小鼠淋巴细胞增殖的影响 被引量:1

Influences of the 3rd trimester placental factor on mouse lymphocytes proliferation
下载PDF
导出
摘要 通过晚孕期胎盘因子(PF)对小鼠淋巴细胞体外增殖的作用,探讨PF对正常机体免疫系统和免疫功能的效应。分离小鼠淋巴细胞,用ConA刺激其增殖,并分别与晚孕期不同浓度的PF作用,于48 h和72 h用活体染料羧基荧光素乙酰乙琥珀酰亚胺酯(CFSE)标记,流式细胞术检测增殖。于48 h碘化丙啶染色,流式细胞术检测细胞周期分布。结果显示,晚孕期PF在48 h和72 h时间点均能显著促进ConA诱导的小鼠淋巴细胞增殖反应,且效应与剂量呈正相关。晚孕期各浓度PF组G0期所占比率均显著低于对照组,且浓度越大,比率越低,组间两两比较有统计学意义。各浓度PF组S期所占比率均显著高于对照组,各浓度PF组G2/M期所占比率均显著高于对照组,25%PF组G2/M期所占比率均显著高于5%PF组和15%PF组。晚孕期PF通过促进小鼠淋巴细胞由G1期向S和G2/M期而促进ConA刺激小鼠淋巴细胞的增殖反应,提示PF具有免疫调节的功能,可以提高机体的免疫功能。 To study the effects of the 3rd trimester placental factor (PF) on mouse lymphocytes proliferation, and to explore their possible role in immune function. ConA stimulated mouse lymphocytes were treated with different concentrations of the 3rd trimester PF, and then labeled with CFSE or propidium iodide. Lymphocytes proliferation was measured at 48 h and 72 h and cell cycle distribution was examined at 48 h with flow cytometry. The PF at diffecent concentrations increased significantly the ConA-stimulated mouse lymphocytes proliferation in a dose-dependent manner. The percentages of GO of all 3rd trimester PF groups were significantly lower than that of the control group respectively, while the percentages of S were significantly higher when compared with the control group. The percentages of G2/M of all 3rd trimester PF groups were significantly higher than that of the control group, and the percentage of G2/M of 25% PF group was significantly higher than those of 5% and 15% PF groups respectively. It is evident that the 3rd trimester PF can enhance mouse lymphocytes proliferation, and thus improving the immune function.
出处 《现代免疫学》 CAS CSCD 北大核心 2007年第2期125-128,共4页 Current Immunology
关键词 胎盘因子 人免疫缺陷病毒 CFSE 淋巴细胞 增殖 细胞周期分布 placental factor HIV CFSE lymphocyte proliferation cell cycle distribution
  • 相关文献

参考文献4

二级参考文献19

  • 1Arsenault AL, Lhotak S, Hunter WL, et al. Taxol(paclitaxel) involution of articular cartilage destruction in collagen induced arthritis: an ultrastructural demonstration of an increased superficial chondroprotective layer[J]. Rheumatology, 2000,27(3):582-588.
  • 2Cao L, Sun D, Cruz T, et al. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel [J]. Neuroimmunology, 2000,108(1-2):103-111.
  • 3Tange S, Scherer MN, Graeb C, et al. The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat hear transplant model[J]. Transplantation, 2002,73(2):216-223.
  • 4Rowinsky EK, Goolsby GL, Wahl AF, et al. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle[J]. Int J Cancer, 1994, 57(6):847-855.
  • 5Vyas DM, Kadow JF. Paclitaxel: a unique tubulin interacting anticancer agent[J]. Prog Med Chem, 1995,32(1):289-337.
  • 6Blagosklonny MV, Schulte T, Nauyen P, et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1and represents a novel c-Raf-1 signal transduction pathway [J].Cancer Res, 1996, 56(8): 1851-1854.
  • 7Steelman LS, Hu W, Konoplera M, et al. Raf-1 and Bcl-2induce distinct and common pathways that contribute to breast cancer drug resistance [ J]. Clin Cancer Res, 2003,9(3):1161-1170.
  • 8Oyaizu H , Adachi Y, Taketain S, et al. A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis[J]. Mol Cell Biol Res Commun, 1999,2(1):36-41.
  • 9Pucci B, Belllncampi L, Tafani M, et al. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2phosphorylation[J]. Exp Cell Res, 1999, 252(1):134-143.
  • 10Srivastava RK, Sasaki CY, Hardwick JM, et al. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced fas ligand transcription[J]. J Exp Med, 1999,190(2):253-265.

共引文献4

同被引文献20

  • 1Clark P A. Mother-to-child transmission of HIV in Botswana: an ethical perspective on mandatory testing [J]. Dev World Bioeth, 2006, 6(1) : 1-12.
  • 2Cooper E R, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission [J]. J Acquit Immune Defic Syndr, 2002, 29(5) : 484-494.
  • 3Dorenbaum A, Cunningham C K, Gelber R D, et al. Two- dose intrapartum/newbom nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial [J]. JAMA, 2002, 288(2) : 189-198.
  • 4Abrams E J, Wiener J, Carter R, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children [ J ]. AIDS, 2003, 17(6): 867-877.
  • 5Sharma U K, TrujiUo J, Song H F, et al. A novel factor produced by placental cells with activity against HIV-1 [ J ]. J Immunol, 1998, 161(11):6406-6412.
  • 6Philpott S M. HIV-1 coreceptor usage, transmission, and disease progression [ J]. Curr HIV Res, 2003, 1 (2) : 217-227.
  • 7Davenport M P, Zaunders J J, Hazenberg M D, et al. Cell turnover and cell tropism in HIV-1 infection [ J ] . Trends Microbiol, 2002, 10(6) : 275-278.
  • 8Bustamante S, Garcia Y, Garrido H, et al. CXCR-4 and CCR-5 expression in normal term human placenta [ J ]. Invest Clin, 2005 , 46( 1 ) : 25-35.
  • 9Ishii M, Hayakawa S, Suzuki M K, et al. Expression of functional chemokine receptors of human placental cells [ J ] . Am J Reprod Immunol, 2000, 44(6) : 365-373.
  • 10Kumar A, Kumar S, Dinda A K, et al. Differential expression of CXCR4 receptor in early and term human placenta [J]. Placenta, 2004, 25(4): 347-351.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部